First-in-class small molecule inhibitors of ICOS/ICOSL interaction as a novel class of immunomodulators.
Ontology highlight
ABSTRACT: The interaction of the inducible co-stimulator (ICOS) with its ligand (ICOSL) plays key roles in T-cell differentiation and activation of T-cell to B-cell functions. The ICOS/ICOSL pathway is a validated target for T-cell lymphomas induced by the proliferation of T-follicular helper (Tfh) cells. Moreover, the inhibition of ICOS/ICOSL interaction can decrease the enhancement of immunosuppressive regulatory T cells (Tregs) in both hematologic malignancies and solid tumors. However, targeting ICOS/ICOSL interaction is currently restricted to monoclonal antibodies (mAbs) and there are no small molecules in existence that can block ICOS/ICOSL. To fill this gap, we report herein the first time-resolved fluorescence resonance energy transfer (TR-FRET) assay to evaluate the ability of small molecu
SUBMITTER: Abdel-Rahman SA
PROVIDER: S-EPMC10507805 | biostudies-literature | 2023 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA